Shares of PureTech Health plc (LON:PRTC – Get Free Report) crossed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of GBX 122.95 and traded as low as GBX 120. PureTech Health shares last traded at GBX 120.40, with a volume of 10,714,180 shares trading hands.
PureTech Health Stock Performance
The stock’s 50-day moving average price is GBX 116.81 and its 200-day moving average price is GBX 122.95. The company has a current ratio of 4.60, a quick ratio of 2.51 and a debt-to-equity ratio of 4.78. The company has a market capitalization of £295.20 million, a P/E ratio of -2.34 and a beta of 0.77.
PureTech Health Company Profile
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.
Further Reading
- Five stocks we like better than PureTech Health
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
